We’re thrilled to announce that, following our strategic combination with atai Life Sciences, Beckley Psytech is now part of AtaiBeckley, a global leader in transformative mental health therapies. Follow us at @ataibeckley and on our website: ataibeckley.com.

We're looking forward to sharing data on BPL-003 and SSRIs at the CNS Summit in Boston next week. Make sure to drop by to learn more. beckleypsytech.com/posts/bec…

[FOR INVESTORS AND MEDIA] The FDA has granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression. This milestone validates our strong Phase 2b data and accelerates our path forwards to Phase 3. beckleypsytech.com/posts/ata…

We are excited to present data on BPL-003 and anhedonia at ECNP this weekend. Make sure to swing by to learn more! beckleypsytech.com/posts/bec…

We’re proud to share clinical data from our open-label Phase 2a study of BPL-003 in patients with treatment-resistant depression (TRD), investigating the effects of a two-dose induction regimen. Read more here: beckleypsytech.com/posts/ata…

Our CEO & Co-Founder, Cosmo Feilding Mellen, joined @Labiotech_eu’s Beyond Biotech podcast to discuss how next-gen psychedelics could help patients with treatment-resistant depression. Listen here podcast.labiotech.eu/1995493… #MentalHealth #Psychedelics #Biotech

Today, $ATAI announced outstanding Phase 2b data for BPL-003 (5-MeO-DMT). In parallel, core shareholders – including myself and pharma company @ferring – demonstrated conviction by investing $50 million together with top-tier biotech funds. I firmly believe psychedelics have the potential to heal millions and fundamentally transform mental health treatment. In doing so, they will make a deep, positive dent in the universe. Especially in the times ahead, we humans need psychedelics more than ever. My hope is for @atai_life to lead this revolution – scientifically, commercially, and spiritually. atai is the greatest entrepreneurial endeavour of my life, and I believe it will yield rich returns – both financial and emotional – for everyone involved. Check out my latest blog post: christianangermayer.substack…

Breaking: Positive topline data from our Phase 2b study of BPL-003 in treatment-resistant depression. A key step toward Phase 3 and our mission to deliver faster, longer-lasting psychedelic treatments to those who need them most. beckleypsytech.com/posts/ata…

We’re proud to join @MentalHealthAm's Regional Policy Council - a national network shaping mental health policy through lived experience, collaboration and innovation. Together, we aim to ensure emerging treatments lead to real-world impact.

Prof. John Marsden (King’s College London) and Dr. Anya Ermakova (Beckley Psytech) will be sharing novel clinical and micro-phenomenological data from our Phase IIa study of BPL-003 for Alcohol Use Disorder at the 2025 CPDD Annual Meeting. 🔗 Learn more: beckleypsytech.com/posts/res…

NEWS: Beckley Psytech and @atai_life ($ATAI) to combine to form a global leader in psychedelic mental health therapies. Together, we’re accelerating innovation for those in need. Learn more: beckleypsytech.com/posts/ata…

Today we announced positive topline results from our Phase IIa study of BPL-003 in combination with SSRIs for treatment resistant depression. Read more on our website: beckleypsytech.com/posts/pos…

We will be presenting data from our Phase IIa study of BPL-003 for TRD at #SOBP2025 in Toronto tomorrow at 5pm EDT. Looking forward to connecting with the scientific community. beckleypsytech.com/posts/bec…

It's Brain Awareness Week - the perfect time to highlight the first-of-its-kind brain imaging study going on at @imperialcollege with BPL-003. Check out our Q&A with the experts behind the study (@neurodelia, @tommaso_barba) below.

We have completed enrolment in the core stage of our Phase IIb study of BPL-003 for Treatment Resistant Depression. Grateful to our trial participants & partners who made this study happen! beckleypsytech.com/posts/bec…

Today is International Day of Women and Girls in Science! 🌍🔬 At Beckley Psytech, we’re celebrating the brilliant women in our team who are shaping the future of science. Hear about some of their experiences below. #IDWGS #WomenInSTEM

Topline data from our Phase IIa study of BPL-003 for Alcohol Use Disorder show that a single dose was well-tolerated and delivered a meaningful and sustained reduction in alcohol use and Heavy Drinking Days over a 3-month evaluation period. beckleypsytech.com/posts/bec…

Initial findings from our Phase IIa study of ELE-101 for depression shows that a single 10-minute infusion is well-tolerated, induces rapid and lasting antidepressant effects, and allows patients to be ready for discharge in ~2 hours. Read more here: t.ly/mGgPP

🎙️ In this fascinating episode of @healthtechpod with @JamesSomauroo, our CEO, Cosmo Feilding Mellen, shares his insights on psychedelics, consciousness, and mental health innovation. 🎧 Listen here: open.spotify.com/episode/3Ed…

ICYMI: Our CEO, Cosmo Feilding Mellen, caught up with @TIME to discuss how our novel short-acting, psychedelic-based therapies could revolutionise the treatment of mental health conditions. Learn more here: time.com/7027173/new-psyched…